
Abstract

Background. Covid-19, the disease caused by SARS-CoV-2, is associated with significant respiratory-related morbidity and mortality. Angiotensin receptor blockers (ARBs) have been postulated as tentative pharmacological agents to treat Covid-19-induced lung inflammation.

Trial design. This trial is a parallel group, randomized, two arm, open label, multicenter superiority trial with 1:1 allocation ratio. Methods. Participants included patients who were 18 years of age or older and who had been hospitalized with confirmed Covid-19 with 4 or fewer days since symptom onset. Exclusion criteria included intensive care unit admission prior to randomization and use of angiotensin receptor blocker or angiotensin converting enzyme inhibitors at admission. Participants in the treatment arm received telmisartan 80 mg bid during 14 days plus standard care. Participants in the control arm received standard care alone.

Primary outcome was to achieve significant reductions in plasma levels of C-reactive protein in telmisartan treated Covid-19 patients at day 5 and 8 after randomization. Key secondary outcomes included time to discharge evaluated at 15 days after randomization and admission to ICU and death at 15- and 30-days post randomization. We present here a preliminary report.

Results. A total of 78 patients were included in the interim analysis, 40 in the telmisartan and 38 in the control groups. CRP levels at day 5 in the control group were 51.1 ± 44.8 mg/L (mean ± SD; n=28) and in the telmisartan group were 24.2 ± 31.4 mg/L (mean ± SD; n=32, p<0.05). At day 8, CRP levels were 41.6 ± 47.6 mg/L (mean ± SD; n=16) and 9.0 ± 10.0 mg/L (mean ± SD; n=13, p < 0.05) in the control and telmisartan groups, respectively. Also, analysis of time to discharge by Kaplan-Meier method showed that telmisartan treated patients had statistically significant lower time to discharge (median time to discharge control group=15 days; telmisartan group=9 days). No differences were observed for ICU admission or death. No significant adverse events related to telmisartan were reported.

Conclusions. In the present preliminary report, despite the small number of patients studied, ARB telmisartan, a well-known inexpensive safe antihypertensive drug, administered in high doses, demonstrates anti-inflammatory effects and improved morbidity in hospitalized patients infected with SARS-CoV-2, providing support for its use in this serious pandemia (NCT04355936).
Title:

Authors
Mariano Duarte MD PhD1,3,16, Facundo Pelorosso MD PhD1,17,18, Liliana Nicolosi MD9, M. Victoria Salgado MD PhD19,20, Héctor Vetulli MD14, Analía Aquieri MD3, Francisco Azzato MD PhD7, Mauro Basconcel MD7, Marcela Castro Bioq.8, Javier Coyle MD4, Ignacio Davolos MD4, Eduardo Esparza MD11, Ignacio Fernandez Criado MD5, Rosana Gregori MD10, Pedro Mastrodonato MD12, María C. Rubio MD9, Sergio Sarquis MD5, Fernando Wahlmann MD13 and Rodolfo P. Rothlin MD2,15,17.

1Joint first authorship.
2Corresponding author.

Affiliations
3Laboratorio de Hipertensión, División de Cardiología, Hospital de Clínicas “José de San Martín”, Facultad de Medicina, Universidad de Buenos Aires.
4División de Cardiología, Hospital de Clínicas “José de San Martín”, Facultad de Medicina, Universidad de Buenos Aires.
5Sección de Tecnología Educativa e Informática Médica, Hospital de Clínicas “José de San Martín”, Facultad de Medicina, Universidad de Buenos Aires.
6Unidad de Cuidados Intensivos, Hospital de Clínicas “José de San Martín”, Facultad de Medicina, Universidad de Buenos Aires.
7Departamento de Medicina, Hospital de Clínicas “José de San Martín”, Facultad de Medicina, Universidad de Buenos Aires.
8Laboratorio de Terapia Intensiva y Urgencias, Hospital de Clínicas “José de San Martín”, Facultad de Medicina, Universidad de Buenos Aires.
9División de Cardiología, Hospital Español de Buenos Aires.
10Servicio de Guardia, Hospital Español de Buenos Aires.
11Unidad de Cuidados Intensivos, Hospital Español de Buenos Aires.
12Laboratorio Central, Hospital Español de Buenos Aires.
13Departamento de Medicina Interna, Hospital Español de Buenos Aires.
14Servicio de Electrofisiología Cardíaca, Arritmias y Marcapasos, Sanatorio Otamendi y Miroli.
15Sociedad Argentina de Farmacología Clínica, Asociación Médica Argentina.
16Segunda Cátedra de Fisiología, Facultad de Medicina, Universidad de Buenos Aires.
17Asociación Argentina de Medicamentos, Ciudad de Buenos Aires, Argentina.
18Servicio de Anatomía Patológica, Hospital de Alta Complejidad El Calafate SAMIC.
19Centro de Estudios de Estado y Sociedad, Ciudad de Buenos Aires, Argentina.
20Servicio de Medicina Familiar, Hospital de Alta Complejidad El Calafate SAMIC.

Authorship
The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Copyright
The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in BMJ editions and any other BMJPGL products and sublicences such use and exploit all subsidiary rights, as set out in our licence.

Conflict of interests
All authors have completed the Unified Competing Interest form (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.

Details of contributors
Guarantor: Rodolfo P. Rothlin.
The lead author and guarantor, Rodolfo P. Rothlin, affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Ethics
The study protocol and its modifications were approved by the ethics committee of Hospital de Clínicas “José de San Martín”, Facultad de Medicina, Universidad de Buenos Aires and by the Institutional Review Board at Hospital Español de Buenos Aires.

Funding: No funding sources to report.

Role of study sponsors: The School of Medicine, University of Buenos Aires, provided material support through permission to use Hospital de Clínicas facilities to carry out the trial. Also, all biochemical determinations at Hospital de Clínicas were carried out at its Central Laboratory Facility. Hospital Español de Buenos Aires provided material support through permission to use its facilities to carry out the trial. Also, all biochemical determinations at this site were carried out at the Central Laboratory Facility at Hospital Español. Laboratorios Elea Phoenix provided the telmisartan tablets used for the study and provided assistance in submitting the registration of this trial to www.ClinicalTrials.com.
The sponsors had no role in the design of this study neither had any role during its execution, analyses, interpretation of the data, or decision to submit results.

Dissemination declaration: We plan to disseminate the results to study participants and or patient organisations.
Introduction

The SARS-CoV-2 virus enters the airway and binds the host cell (alveolar type 2) through the interaction of the structural protein S (Spike) with the protein membrane ACE2 (angiotensin-converting enzyme 2) (1). The virus-ACE2 complex is internalized by endocytosis effectively sequestering (apparent down-regulation) ACE2 which in turn loses its function catalyzing the degradation of angiotensin II to angiotensin 1-7. Angiotensin II acting on AT1 receptors causes vasoconstriction, apoptosis, proinflammatory effects, and fibrosis. Angiotensin 1-7 acting on Mas receptors causes opposite effects: it mediates vasodilation and anti-inflammatory actions (2).

Coronavirus disease 2019 (Covid-19), the disease caused by SARS-CoV-2, is associated with significant respiratory-related morbidity and mortality, as well as elevation of systemic inflammatory biochemical markers (3). Among them, one of the most relevant is C-reactive protein (CRP) whose serum levels can be used as an independent factor to predict the disease severity and progression (4, 5). CRP is a pentameric protein induced by IL-6 in the liver and the expression level increases rapidly and significantly during acute inflammatory responses (6). In Covid-19 patients serum levels of CRP rise during the initial phase of infection, with continued increments during the first week of the disease to then fall dramatically in a few days to normal values if recovery ensues (7, 8). CRP has been shown to correlate with clinical course and in critically ill patients can even rise or remain high (4).

It has been proposed that in Covid-19 patients the loss of ACE2 function in alveolar cells results in a deviation of the homeostatic balance of the renin angiotensin system leading to increased tissue concentration of angiotensin II and reduced levels of its physiological antagonist angiotensin 1-7 (3). Angiotensin II can promote apoptosis in alveolar cells, which, in turn, initiates an inflammatory process with release of proinflammatory cytokines, establishing a self-powered cascade (9) leading, in severe cases, to Acute Respiratory Distress Syndrome (ARDS) (10). Elevation of angiotensin II in other tissues seems to play a role in promoting inflammation and tissue injury (myocarditis, renal injury, etc). Angiotensin receptor blockers (ARBs), a well-known anti-hypertensive drug group that blocks AT1 receptor, have been postulated as tentative pharmacological agents to treat Covid-19-induced lung inflammation (11). Data from retrospective studies from Covid-19 patients have provided some evidence to support that hypothesis (12). However, no conclusive data from a prospective randomized trial on the use of ARBs on Covid-19 patients are available. Pharmacological analysis made by Rothlin et al. (13) has postulated that telmisartan may be the best candidate to study. Therefore, the objective of this study was to assess whether telmisartan 80 mg b.i.d. would be effective in reducing lung inflammation and CRP levels at 5 and 8 days of treatment in Covid-19 hospitalized patients. We present here a preliminary report of that study.
Methods

Trial design and settings
We conducted this two-arm, multicenter, randomized, open-label, controlled trial at two academic hospitals in Ciudad de Buenos Aires, Argentina: Hospital de Clínicas “José de San Martín” or site 1 (HCJSM, University of Buenos Aires main hospital) and Hospital Español de Buenos Aires or site 2 (HEBA, a community hospital). The protocol was approved by the ethics committee at HCJSM and the institutional review board at HEBA. The trial was funded by the participating hospitals. Laboratorios Elea Phoenix S.A. donated and supplied the trial drugs and provided administrative support for registration of this trial at www.ClinicalTrials.gov. Laboratorios Elea Phoenix S.A. had no role in the conduct of the trial, the analysis, or the decision to submit the manuscript for publication. The authors vouch for the completeness and accuracy of the data and for the fidelity of the trial to the protocol.

Participants
The trial included participants who were 18 years of age or older and who had been hospitalized with PCR-confirmed Covid-19 infection with 4 or fewer days elapsed since symptom onset. Exclusion criteria were: admission to Intensive Care Unit (ICU) prior to randomization, illness symptoms beginning more than 4 days prior to randomization, pregnancy, breast feeding, major hypersensibility to ARBs, systolic blood pressure < 100mmHg, serum potassium greater than 5.5 mEq/L, AST and/or ALT > 3 times the upper limit of normal, serum creatinine higher than 3 mg/dl, treatment with angiotensin converting enzyme inhibitor (ACEi) or ARB at admission. All the patients provided written informed consent before randomization.

Randomization and intervention
Patients were randomly assigned in a 1:1 ratio to receive standard care (control group) or standard care plus telmisartan 80 mg twice daily for 14 days. Simple randomization was performed using the GraphPad QuickCalcs Web site by a statistician with no contact with patient care (MVS). Enrollment was conducted by LN, RG, MR, EE, FW and MD. LN and MD assigned participants to interventions. No concealment mechanism was implemented. Patients who received plasma from convalescent patients were censored from the date of plasma administration onwards. Guidance was provided to the investigators about how to adjust or interrupt treatment according to side effects and laboratory abnormalities.

Outcomes
Reductions of C reactive protein levels at day 5 and 8 were chosen as primary outcome. C-reactive protein (CRP) serum levels can be used as an independent factor to predict the disease severity and progression (4, 7). Secondary outcomes included admission to ICU within 15 and 30 days from randomization, occurrence of mechanical ventilation within 15 and 30 days from randomization, death within 15 and 30 days from randomization, composite occurrence of admission to ICU, mechanical ventilation or death within 15 and 30 days from randomization, proportion of patients not requiring supplemental oxygen at day 15 (or with an oxygen saturation lower than 96% while breathing room air), time from randomization to discharge up to day 15 from randomization, and significative differences in serum lactate dehydrogenase levels at day 5 and 8. All the trial outcomes were assessed by the site investigators, who were aware of the trial-group assignments.

Sample size calculation and protocol changes
For sample size calculations, we used our main outcome level as reference (CRP), and a repeated measures model. Calculations were done using the GLIMMPSE (General Linear Mixed Model Power and Sample Size) software (Sproston & Ashworth, 2018), freely available at https://glimmpse.samplesizeshop.org/. We determined a 0.80 power and a type I error rate of 0.05, and chose the Hotelling Lawley Trace test.

We assumed an initial CRP level of 60 mg/L in both groups, with an elevation on day 5 in the control group (up to 72 mg/L, 20% more) and a descend in the telmisartan group to 36 mg/L (40% less). We then assumed that the mean value decreased at day 8 in both groups.

Accounting for variability on these assumptions, we used a scale factor of 0.5 for the mean and 2 for the standard deviation. Further detail is provided in the Statistical analysis plan in the trial protocol.

We obtained a total population sample of 390 participants (195 in each group), which we roughly approximated to 400 (200 in each group).

Initial design included CRP level comparison at day 8 and 15. However, given the clinical evolution of the study population (i.e. median time to discharge in the control group) and the dynamics of CRP in Covid-19 patients, measurements were made at day 5 and day 8 to provide a more complete dataset since many patients would be discharged by day 15. Therefore, endpoints were reestablished at day 5 and 8. Composite occurrence of admission to ICU, mechanical ventilation or death between randomization and 15 and 30 days, proportion of patients not requiring supplemental oxygen at day 15, time to discharge from randomization at 15 days were also added as secondary outcomes at that point.

Statistical analysis

This is a two arm, open label, randomized trial testing a superiority hypothesis with a two-sided type I error rate of 0.05 (refer to the trial protocol for more information on statistical analysis plan).

Descriptive analysis was performed using the appropriate summary statistics (e.g., proportions for categorical data, means with 95% confidence intervals for continuous data, median for time-to-event data). Comparison of C-reactive protein and LDH levels at day 1, 5 and 8 were analyzed by fitting a mixed model. Mixed-effects model analysis for repeated measures was followed by a Holm-Šídák multiple comparison test. Analysis of time to discharge was done calculating proportions using the Kaplan-Meier method, and the resulting curves were compared by a log-rank test. Differences in proportions (ICU, mechanical ventilation, death, need for oxygen supplementation at day 15) were compared by Chi-square test.

We planned one interim analysis to be conducted on July 31st 2020.

Analyses were performed using GraphPad Prism version 8.4.3 (686) for Windows.

Patient and Public Involvement.

There is no patient and public involvement to declare.
Results

Characteristics of the participants

We recruited 82 participants with confirmed Covid-19 (July 30th 2020). The numbers of enrolled patients were 66 and 16 at site 1 and site 2, respectively. A total of 41 patients were randomly assigned to receive telmisartan and 41 patients to receive standard care (control group) (Figure 1). The first patient underwent randomization on May 14, 2020; the last patient before interim analysis underwent randomization on July 30, 2020. Four patients were excluded after randomization (3 patients met exclusion criteria and 1 patient did not receive treatment).

3 patients had telmisartan treatment discontinued before day 14 because of mechanical ventilation or administration of plasma from convalescent patients.

At the time of the database freeze (July 31, 2020), a total of 3 patients in the control group and 3 patients in the telmisartan group had not reached day 15 after randomization.

Demographic and clinical characteristics of participants are depicted in Table 1.

Primary outcomes

Patients in the telmisartan group had a lower CRP serum level than patients in the control group at day 5 (control 51.1 ± 44.8 mg/L, n=28, as compared with telmisartan mean 24.2 ± 31.4 mg/L, n=32, p<0.05, all values are expressed as mean ± SD). Also, CRP serum levels were lower at day 8 in patients treated with telmisartan than those in the control group (mean 9.0 ± 10.0 mg/L, n=13, as compared with 41.6 ± 47.6 mg/L, n=16, respectively, p < 0.05) (Figure 2).

Secondary outcomes

Results from clinical secondary outcomes are shown in Table 2. Preliminary results from the 78 patients analyzed (40 assigned to telmisartan and 38 assigned to standard care) with data available up to 15 days after randomization indicated that those who received telmisartan had a median discharge time of 9 days, as compared with 15 days in those who received standard care (Log-rank (Mantel-Cox) p=0.0124), hazard ratio (logrank) for discharge telmisartan/control 2.02 (95% CI, 1.14 to 3.59).

No differences were observed for ICU admission, mechanical ventilation, death or the composite outcome of first occurrence of ICU admission, mechanical ventilation or death at day 15 or day 30 (Table S1). A detail of patient's characteristics and causes of death can be found in the Supplementary Appendix (Table S2).

No differences were observed for ICU admission, mechanical ventilation, death or the composite outcome of first occurrence of ICU admission, mechanical ventilation or death at day 15 or day 30 (Table S1). A detail of patient’s characteristics and causes of death can be found in the Supplementary Appendix (Table S2).

The proportion of inpatients needing supplementary O₂ at day 15 was significantly higher in the control group (13 out of 14) than in telmisartan treated patients (2 out 4; p<0.05)

No adverse events related to telmisartan were reported. No differences were observed in blood pressure between telmisartan and control group at day 5 or 8 (Table S3).

No differences were observed in LDH levels at days 5 or 8 between telmisartan and control group (Figure S1 and table S4).

Hematological indices and additional biomarkers at day 5 and day 8 are shown in the Supplemental Appendix (Figure S1 and table S4).
Discussion

In the present preliminary report, despite the small number of patients studied, telmisartan decreased plasma CRP levels rapidly and in a sustained manner, and produced an improvement in the clinical evolution of patients hospitalized with Covid-19.

In February 2020, Liu, Y et al. (3) suggested that ARBs may be used as treatment for ICU patients infected with SARS-CoV-2. This was rapidly followed by an editorial comment entitled "Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics" (11) and, in April, the initiation of recruitment for several prospective clinical trials in order to evaluate different ARBs (losartan, NCT04312009, NCT04311177, NCT04340557; valsartan, NCT04335786; and telmisartan, NCT04355936) in Covid-19 patients.

Liu, Y et al. (3) reported 12 Covid-19 patients and detected that plasma levels of angiotensin II were markedly elevated and significantly higher than those of healthy individuals. Additionally, the plasma level of angiotensin II in Covid-19 patients was strongly associated with the viral load of SARS CoV-2 and pulmonary injury, suggesting that the imbalance of the renin-angiotensin system (RAS) in these patients was caused by the entry into the lungs of the coronavirus and the consequent downregulation of ACE2.

Recently, Orianne Villard et al. (14), in a study that included 44 Covid-19 patients, found that patients with severe clinical status had significantly higher plasma levels of aldosterone than those with mild or moderate clinical status. Furthermore, plasma CRP levels were correlated with the severity of Covid-19 and, when the plasma aldosterone level was greater than 102.5 pmol/L, a positive correlation was observed between aldosterone and CRP plasma level. Aldosterone is synthesized by aldosterone synthase in the adrenal cortex in response to high (K+) and angiotensin II. Therefore, the increase in plasma levels of aldosterone in Covid-19 patients strongly suggests that it corresponds to an increase in plasma levels of angiotensin II as a consequence of the inhibition of its metabolism caused by the downregulation phenomenon of ACE2 (14).

In lung tissue, coronavirus infection markedly reduces cell surface ACE2 expression producing a RAS disbalance which results in an elevation of angiotensin II and a reduction in angiotensin 1-7 extracellular concentrations. Taking into account that angiotensin II has proinflammatory properties and that angiotensin 1-7 has anti-inflammatory properties, this imbalance could induce the development of AT1 receptor-dependent inflammatory processes. In the lung, a variety of cells express RAS, and pneumocytes, macrophages, epithelial and endothelial cells may release proinflammatory cytokines through AT1 receptor activation (15). In this sense, it is important to indicate that plasma levels of IL-6 are directly correlated with the severity of Covid-19 (4, 16). Furthermore, serum levels of CRP, a protein synthesized by the liver induced by the action of IL-6 during the acute phase of an inflammatory / infectious process (6), are considered an independent predictive biomarker of disease severity in patients with Covid-19 on admission (4). In addition, in recent years, solid experimental information indicates that CRP has inflammatory amplifying properties in injured tissues (6, 17).

To evaluate the involvement of RAS in systemic inflammation and clinical evolution of hospitalized Covid-19 patients, this protocol was designed using telmisartan, an AT1 receptor blocker. Telmisartan was chosen for its pharmacokinetic and pharmacodynamic properties (13). Telmisartan, which is well absorbed after oral administration, is the ARB with the longest plasma half-life (24 h), it reaches the highest tissue concentrations due to its high lipid solubility and
high volume of distribution (500 L), and dissociates more slowly after binding to the AT1 receptor, causing an apparently irreversible block (18, 19). In addition, the use of a daily dose of 160 mg was defined, higher than the maximum recommended antihypertensive, taking into account its “placebo like” adverse effect profile (20)).

In the present study, treatment with telmisartan in patients with Covid-19 produced a significant reduction of serum CRP levels 5 and 8 days after admission (Figure 2). The differences observed between control and telmisartan group (51.1 vs 24.2 mg/L at day 5 and 41.6 vs 9.0 mg/L at day 8) might be clinically relevant considering that patients with CRP levels higher than 40 mg / L are more likely to have severe complications. Simultaneously, telmisartan was superior to standard care in significatively shortening the time to discharge in adults hospitalized with Covid-19 (Figure 3). These data, when taken together, indicate that telmisartan reduced morbidity in Covid-19 patients in this study. It has been shown that most patients only develop antibodies against SARS-COV2 after 7 days from disease onset and that, by day 15, IgM and IgG antibodies are detected in approximately 90% and 80% of the patients (21). Also, Sun et al. (22) showed that, as Covid-19 progressed, the increase of IgG specific to S protein positively correlated with a decrease of CRP in non-ICU patients. Therefore, the rapid anti-inflammatory effect of telmisartan may be highly valuable in improving the final outcome of the clinical course of Covid-19 patients.

Main limitations of the study are the lack of blinding, the exclusion of ICU patients on randomization, the low number of enrolled patients given the preliminary nature of this report, and the restriction to patients with a relatively short time from symptom onset to randomization. Therefore, additional rigorous studies are warranted to determine its value as a therapeutic tool in the Covid-19 clinical spectrum.

In synthesis, the present results constitute strong evidence in favor of the involvement of the RAS in the inflammatory process observed in hospitalized Covid-19 patients and that the ARB telmisartan, a well-known inexpensive safe antihypertensive drug, administered in high doses, demonstrates anti-inflammatory effects and improved morbidity in hospitalized patients infected with SARS-CoV-2, providing support for its use in this serious pandemia.
References


Acknowledgements
The authors would like to acknowledge Dr. Carlos R. Rojo, MD. for sharing our hypothesis and promoting institutional support for the conduction of this study.
The authors would also like to acknowledge Dr. Raúl Mejía for the critical reading of this manuscript.

Data sharing
Data of individual participants that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be made available upon publication for 5 years at a third-party website (DOI: 10.5281/zenodo.3970223)
### Tables

Table 1. Demographic and Clinical Characteristics at Baseline. *p<0.05. COPD, Chronic Obstructive Pulmonary Disease; CRP, C-reactive protein; LDH, lactate dehydrogenase.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th><strong>control (n=38)</strong></th>
<th><strong>telmisartan (n=40)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age -yr</td>
<td>63.8 ± 18.7</td>
<td>60.1 ± 17.8</td>
</tr>
<tr>
<td>Female – no (%)</td>
<td>17 (44.7)</td>
<td>13 (32.5)</td>
</tr>
<tr>
<td><strong>Coexisting conditions – no (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>10 (26.3)</td>
<td>14 (35.0)</td>
</tr>
<tr>
<td>COPD</td>
<td>2 (5.3)</td>
<td>7 (17.5)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>5(13.2)</td>
<td>4 (10.0)</td>
</tr>
<tr>
<td>Obesity</td>
<td>2 (5.3)</td>
<td>8 (20.0) *</td>
</tr>
<tr>
<td>Dyslipemia</td>
<td>4 (10.5)</td>
<td>7 (17.5)</td>
</tr>
<tr>
<td>Stroke</td>
<td>1 (2.6)</td>
<td>5 (12.5)</td>
</tr>
<tr>
<td>Asthma</td>
<td>0 (0)</td>
<td>1 (2.5)</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>0 (0)</td>
<td>2 (5.0)</td>
</tr>
<tr>
<td><strong>Clinical characteristics at admission</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Required supplementary O₂ - no (%)</td>
<td>30 (79.0)</td>
<td>35 (87.5%)</td>
</tr>
<tr>
<td>Respiratory rate (bpm)</td>
<td>19.8 ± 3.1</td>
<td>19.5 ± 2</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>53.7 ± 56.7 (38)</td>
<td>72.4 ± 72.3 (36)</td>
</tr>
<tr>
<td>Lymphocyte count (10^9/µL)</td>
<td>1.25 ± 0.1 (37)</td>
<td>1.33 ± 0.1 (36)</td>
</tr>
<tr>
<td>Platelet count (10^9/µL)</td>
<td>200.8 ± 9.7 (38)</td>
<td>235.3 ± 15.8 (36)</td>
</tr>
<tr>
<td>Neutrophil to lymphocyte ratio</td>
<td>4.8 ± 0.8 (37)</td>
<td>7.0 ± 1.5 (37)</td>
</tr>
<tr>
<td>LDH (UI/L)</td>
<td>520.6 ± 267.11 (35)</td>
<td>506.7 ± 30.2 (33)</td>
</tr>
<tr>
<td>D-Dimer (µg/mL)</td>
<td>1.30 ± 0.89 (21)</td>
<td>0.98 ± 0.78 (22)</td>
</tr>
<tr>
<td>Ferritin (ng/mL)</td>
<td>1129.8 ± 290.3 (17)</td>
<td>804.6 ± 132.9 (19)</td>
</tr>
</tbody>
</table>
Table 2. Clinical evolution at 15 days. *p<0.05.

<table>
<thead>
<tr>
<th></th>
<th>control</th>
<th>telmisartan</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of hospital discharges by day 15 (%)</td>
<td>18 (56.4)</td>
<td>29 (79.5)</td>
</tr>
<tr>
<td>Median time to discharge (days)</td>
<td>15</td>
<td>9</td>
</tr>
<tr>
<td>Hazard ratio - discharge telmisartan/control (95% CI)</td>
<td>2.153 (1.180 to 3.929)</td>
<td></td>
</tr>
<tr>
<td>Proportion of hospitalized patients needing supplementary O₂ at day 15</td>
<td>13/14</td>
<td>2/4*</td>
</tr>
</tbody>
</table>
Figures

Figure 1. Enrollment and randomization

- 185 patients assessed for eligibility
  - 103 were excluded
    - 46 ineligible due to exclusion and inclusion criteria
    - 57 were eligible but not randomized
  - 82 underwent randomization
    - 41 assigned to standard care
      - 3 did not meet eligibility criteria
      - 4 underwent early termination due investigational use of plasma
        - 31 completed the study through day 15 (includes death and discharge)
        - 3 were continuing trial, still hospitalized as of database freeze
        - 4 were censored before day 15 due to investigational use of plasma
      - 38 were included in the analysis
    - 41 assigned to telmisartan
      - 1 received all 28 doses of telmisartan
      - 40 received <28 doses of telmisartan
        - 26 recovered
        - 1 died
        - 4 missed doses intermittently
        - 1 discontinued due to admission to ICU/mechanical ventilation
        - 0 discontinued due to adverse events other than death
        - 1 never received treatment
        - 2 underwent early termination due investigational use of plasma
        - 3 were still receiving treatment at time of database freeze
      - 40 were included in the analysis
Figure 2. Serum CRP levels at days 1, 5 and 8 after randomization. Points represent mean ± SEM. * indicate p<0.05.
Days elapsed | control | telmisartan
--- | --- | ---
0.000 | 38 | 40
1.000 |
2.000 | 39 |
3.000 | 37 |
4.000 | 36 |
5.000 | 30 | 31
6.000 | 29 |
7.000 | 28 | 23
8.000 | 25 | 21
9.000 | 23 | 18
10.000 | 16 |
11.000 | 21 | 13
12.000 | 20 | 12
13.000 | 19 | 10
14.000 | 16 |
15.000 | 15 | 6